electroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for “Non-Invasive Vagus Nerve Stimulator”

NEXT STORY
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
PREV STORY
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

electroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for “Non-Invasive Vagus Nerve Stimulator”

NEXT STORY
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
PREV STORY
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

author_avatar
NASDAQ Market News

Relay & Fio to Deploy Fionet Platform Through USAID in 144 Remote Community-Based Healthcare Sites in the Democratic Republic of the Congo

author_avatar
NASDAQ Market News

Anesthesia Circuits and Regional Anesthesia Disposables (Anesthesia and Respiratory Devices) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

author_avatar
NASDAQ Market News